Elicio Therapeutics, Inc. (ELTX)
$2.86-$0.14 (-4.67%) Today
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 4 | 365,252 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
23 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christopher Haqq - Officer | Grant or award | Stock Option (Right to Buy) | 64,643 | $0.00 | - | |
| Peter Demuth - Officer | Grant or award | Stock Option (Right to Buy) | 52,832 | $0.00 | - | |
| Preetam Shah - Officer | Grant or award | Stock Option (Right to Buy) | 60,833 | $0.00 | - | |
| Robert Connelly - Officer | Grant or award | Stock Option (Right to Buy) | 186,944 | $0.00 | - | |
| Robert Connelly - Officer | Grant or award | Common Stock | 73,600 | $0.00 | - | |
| Robert Connelly - Officer | Grant or award | Stock Option (Right to Buy) | 147,200 | $0.00 | - | |
| Preetam Shah - Officer | Grant or award | Common Stock | 24,000 | $0.00 | - | |
| Preetam Shah - Officer | Grant or award | Stock Option (Right to Buy) | 47,900 | $0.00 | - | |
| Peter Demuth - Officer | Grant or award | Common Stock | 20,800 | $0.00 | - | |
| Peter Demuth - Officer | Grant or award | Stock Option (Right to Buy) | 41,600 | $0.00 | - | |
| Christopher Haqq - Officer | Grant or award | Common Stock | 25,400 | $0.00 | - | |
| Christopher Haqq - Officer | Grant or award | Stock Option (Right to Buy) | 50,900 | $0.00 | - | |
 Robert R. Ruffolo - Director | Grant or award | Stock Option (Right to Buy) | 7,900 | $0.00 | - | |
| Julian Adams - Director | Grant or award | Stock Option (Right to Buy) | 7,900 | $0.00 | - | |
| Karen J. Wilson - Director | Grant or award | Stock Option (Right to Buy) | 7,900 | $0.00 | - | |
| Peter Demuth - Officer | Option exercise | Common Stock | 381 | $4.41 | $2K | |
| Peter Demuth - Officer | Option exercise | Stock Option (Right to Buy) | 381 | $0.00 | - | |
| Jay Venkatesan - Director | Other | Common Stock | 50,000 | $0.01 | $500 | |
| Jay Venkatesan - Director | Other | Warrant to Purchase Common Stock | 50,000 | $0.00 | - | |
| Carol Gail Ashe - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Robert R. Ruffolo - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Yekaterina Chudnovsky - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Jay Venkatesan - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Karen J. Wilson - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Julian Adams - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Allen Nissenson - Director | Grant or award | Stock Option (Right to Buy) | 4,100 | $0.00 | - | |
| Robert Connelly - Officer | Grant or award | Stock Option (Right to Buy) | 91,600 | $0.00 | - | |
| Christopher Haqq - Officer | Grant or award | Stock Option (Right to Buy) | 28,200 | $0.00 | - | |
| Peter Demuth - Officer | Grant or award | Stock Option (Right to Buy) | 29,800 | $0.00 | - |
Elicio Therapeutics, Inc. (ELTX) had 4 insider filings in the last 90 days, with the most recent on 2026-07-17. The full record for ELTX runs to 23 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ELTX were filed in the last 90 days.
No insider sales of ELTX were filed in the last 90 days.
This page tracks ELTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ELTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
